Fatigue in inflammatory bowel disease and its impact on daily activities.
Détails
ID Serval
serval:BIB_00961F0DB62B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Fatigue in inflammatory bowel disease and its impact on daily activities.
Périodique
Alimentary pharmacology & therapeutics
Collaborateur⸱rice⸱s
Swiss IBD Cohort Study Group
Contributeur⸱rice⸱s
Abdelrahman K., Ademi G., Aepli P., Thomas A., Anderegg C., Antonino A.T., Archanioti E., Arrigoni E., Aslan N., Bakker de Jong D., Balsiger B., Bastürk P., Bauerfeind P., Becocci A., Bengoa J.M., Biedermann L., Binek J., Blattmann M., Boehm S., Boldanova T., Borovicka J., Braegger C.P., Brand S., Bravo F., Brügger L., Brunner S., Bühr P., Burk S., Burri E., Butter M., Buyse S., Cao D.T., Carstens O., Criblez D.H., D'Angelo F., Saussure P., Degen L., Delarive J., Doerig C., Dora B., Drerup S., Ducrey C., El-Wafa A., Engelmann M., Erdmann-Voisin A., Felley C., Fliegner M., Fraga M., Franc Y., Frei P., Frei R., Fried M., Froehlich F., Furlano R.I., Garzoni L., Geyer M., Girardin M., Golay D., Good I., Bigler U.G., Godat S., Greuter T., Gysi B., Haarer J., Halama M., Haldemann J., Heer P., Heimgartner B., Helbling B., Hengstler P., Herzog D., Hess C., Hessler R., Heyland K., Hinterleitner T., Hirschi C., Hruz P., Juillerat P., Kapoglou I., Kayser S., Keller C., Khalid-de Bakker C., Knellwolf C., Knoblauch C., Köhler H., Koller R., Krieger C., Künzler P., Kusche R., Lehmann F.S., Macpherson A., Maillard M.H., Manz M., Martinho M., Meier R., Meyenberger C., Meyer P., Michetti P., Misselwitz B., Morell B., Mosler P., Moschouri E., Mottet C., Müller C., Müllhaupt B., Musso L., Neagu M., Nichita C., Niess J., Nydegger A., Obialo N., Oropesa C., Peter U., Peternac D., Petit L.M., Pittet V., Pohl D., Porzner M., Preissler C., Raschle N., Rentsch R., Restellini S., Richterich J.P., Riedmüller S., Risti B., Ritz M.A., Rogler G., Röhrich N., Rossel J.B., Roth R., Rueger V., Sagmeister M., Saner G., Sarraj R., Sauter B., Sawatzki M., Scharl M., Scharl S., Schelling M., Schibli S., Schlauri H., Schluckebier D., Schmid D., Schmid S., Schnegg J.F., Schoepfer A., Schreiner P., Seibold F., Seirafi M., Semadeni G.M., Senning A., Sokollik C., Sommer J., Spalinger J., Spangenberger H., Stadler P., Staub P., Staudenmann D., Stenz V., Steuerwald M., Straumann A., Stulz A., Sulz M., Tempia-Caliera M., Thorens J., Truninger K., Tutuian R., Urfer P., Vavricka S., Viani F., Vinzens F., Vögtlin J., Von Känel R., Vouillamoz D., Vulliamy R., Vullièmoz M., Wiesel P., Wiest R., Wöhrle S., Yilmaz B., Zamora S., Zander S., Zeitz J., Zimmermann D.
ISSN
1365-2036 (Electronic)
ISSN-L
0269-2813
Statut éditorial
Publié
Date de publication
01/2021
Peer-reviewed
Oui
Volume
53
Numéro
1
Pages
138-149
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Fatigue is a common symptom of chronic inflammation, including inflammatory bowel disease (IBD), resulting in significant impairment in quality of life.
To identify the prevalence of fatigue in a large IBD cohort compared to the general population, address risk factors, and evaluate its impact on daily life.
We evaluated 1208 IBD patients from the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) and 414 healthy controls. Significant fatigue was defined as a visual analogue scale (VAS-F, range 0-10) score ≥ 4. Secondary endpoints were severity of fatigue and its impact on daily activities with the Fatigue Severity Scale (FSS), with a score ≥ 4 indicative of fatigue. Demographic, IBD-related and psychiatric symptoms were assessed with a multivariate analysis of variance (MANOVA) model optimised for prediction of VAS-F (primary outcome) and FSS scores.
Overall, 672 IBD patients (55.6%) reported significant fatigue compared to 145 (35%) controls (OR 2.71; 95% CI 2.08-3.54; P < 0.001). In IBD, fatigue also significantly affected daily activities (FSS ≥ 4; 405 (33.5%) IBD patients vs 81 (19.6%) controls, P < 0.001). In the MANOVA model, fatigue levels were associated with female gender (coefficient 0.839; 0.556 - 1.123; P < 0.001), younger age at diagnosis (-0.031 per year; -0.042- -0.019; P < 0.001), shorter disease duration (-0.036 per year; -0.050- -0.022; P < 0.001), nocturnal diarrhoea (0.718; 0.295-1.141; P = 0.001), low educational level (P = 0.034) and symptoms of depression and anxiety.
Fatigue is both more frequent and more severe in patients with IBD than in the general population.
To identify the prevalence of fatigue in a large IBD cohort compared to the general population, address risk factors, and evaluate its impact on daily life.
We evaluated 1208 IBD patients from the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) and 414 healthy controls. Significant fatigue was defined as a visual analogue scale (VAS-F, range 0-10) score ≥ 4. Secondary endpoints were severity of fatigue and its impact on daily activities with the Fatigue Severity Scale (FSS), with a score ≥ 4 indicative of fatigue. Demographic, IBD-related and psychiatric symptoms were assessed with a multivariate analysis of variance (MANOVA) model optimised for prediction of VAS-F (primary outcome) and FSS scores.
Overall, 672 IBD patients (55.6%) reported significant fatigue compared to 145 (35%) controls (OR 2.71; 95% CI 2.08-3.54; P < 0.001). In IBD, fatigue also significantly affected daily activities (FSS ≥ 4; 405 (33.5%) IBD patients vs 81 (19.6%) controls, P < 0.001). In the MANOVA model, fatigue levels were associated with female gender (coefficient 0.839; 0.556 - 1.123; P < 0.001), younger age at diagnosis (-0.031 per year; -0.042- -0.019; P < 0.001), shorter disease duration (-0.036 per year; -0.050- -0.022; P < 0.001), nocturnal diarrhoea (0.718; 0.295-1.141; P = 0.001), low educational level (P = 0.034) and symptoms of depression and anxiety.
Fatigue is both more frequent and more severe in patients with IBD than in the general population.
Mots-clé
Anxiety, Cohort Studies, Fatigue/epidemiology, Fatigue/etiology, Female, Humans, Inflammatory Bowel Diseases/complications, Inflammatory Bowel Diseases/diagnosis, Inflammatory Bowel Diseases/epidemiology, Quality of Life, Severity of Illness Index, Surveys and Questionnaires
Pubmed
Web of science
Site de l'éditeur
Création de la notice
23/11/2020 10:27
Dernière modification de la notice
26/07/2023 6:00
Données d'usage
